BetterLife Pharma Appoints Former Cybin CEO Doug Drysdale as Corporate Advisor to Advance Non-Psychiatric LSD Derivative

BetterLife Pharma Inc. has appointed Doug Drysdale, former CEO of Cybin Inc., as Corporate Advisor to advance the company's development of BETR-001 for non-psychiatric indications including cluster headache and migraine. This appointment signals a strategic move to accelerate development of what could become a groundbreaking treatment for neurological conditions that affect millions worldwide.

Drysdale brings substantial pharmaceutical industry experience to BetterLife, having previously led Cybin from molecule inception to Phase 3 trials in just three years. His track record includes growing Alvogen from inception to $500 million in revenues across 35 countries within 5.5 years, establishing research and development operations in New Jersey and a contract research organization in India. He also transformed Norwich Pharmaceuticals by enhancing its manufacturing and R&D capabilities, and as Chairman and CEO of Pernix Therapeutics, he recapitalized the company with $65 million and grew its enterprise value from $80 million to $800 million.

Dr. Ahmad Doroudian, CEO of BetterLife, stated that Drysdale's 35 years of experience delivering successful transactions across various markets and indications will be instrumental in developing BETR-001 for treatment of cluster headache, migraine and neuropathic pain. The appointment comes at a critical juncture as BetterLife advances its patented compound through preclinical and IND-enabling studies.

BETR-001 represents a significant advancement in neurological treatment as a patented stereoisomer of 2-bromo-LSD that is non-hallucinogenic and non-controlled. Previous forms of 2-bromo-LSD have demonstrated safety and tolerability in human studies, with a small clinical study showing meaningful reduction in cluster headache frequency according to research published in Cephalgia in 2010. The compound's unique regulatory status as unregulated means it could potentially be self-administered, eliminating significant treatment barriers for patients suffering from debilitating neurological conditions.

The implications of this development extend beyond BetterLife's pipeline to potentially transform treatment approaches for cluster headaches and migraines, conditions that often respond poorly to existing therapies. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles, while its pending composition and method of use patent could provide protection until approximately 2042. For further information about the company's developments, visit https://www.betterlifepharma.com.

This strategic appointment and the ongoing development of BETR-001 highlight the growing interest in non-psychoactive derivatives of psychedelic compounds for treating neurological disorders. The combination of Drysdale's proven leadership in pharmaceutical development and BetterLife's innovative compound positions the company to potentially address significant unmet medical needs in neurological care, offering hope for patients who have found limited relief from current treatment options.